CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 22 enrolled
Drug / intervention
MR-Guided Prostate SBRTradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04220983
NCT04220983N/ACompleted
CompareCT.gov

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

Weill Medical College of Cornell University·interventional·Posted Jan 7, 2020·Updated Feb 6, 2024

In Brief

A clinical study evaluating MR-Guided Prostate SBRT for Metastatic Prostate Cancer. Completed, enrolled 22 participants across 1 site.

Detailed Summary

Patients with metastatic prostate cancer can undergo MRI-guided prostate Stereotactic body radiation therapy (SBRT) without significant adverse events, similar to what has been reported for patients with localized prostate cancer. We hypothesize that prostate SBRT will be well-tolerated in metastatic prostate cancer patients, with quality of life outcomes similar to what has been reported in non-metastatic prostate cancer patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJan 7, 2020
Enrollment StartJan 27, 2020
Primary CompletionFeb 28, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.5 years ago

Interventions

MR-Guided Prostate SBRTradiation

Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.